USPH Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of 11.82%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat Encompass Health Corp.'s return on equity of 24.34%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 20.42%. On the other hand Encompass Health Corp. has an analysts' consensus of $140.33 which suggests that it could grow by 41.22%. Given that Encompass Health Corp. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe Encompass Health Corp. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.290, which suggesting that the stock is 28.981% more volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.756, suggesting its less volatile than the S&P 500 by 24.396%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.06%. Encompass Health Corp. offers a yield of 0.73% to investors and pays a quarterly dividend of $0.19 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. Encompass Health Corp. pays out 14.35% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. U.S. Physical Therapy, Inc.'s net income of $19.7M is lower than Encompass Health Corp.'s net income of $174.7M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 36.80x while Encompass Health Corp.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.75x versus 1.75x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of 14.55%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 20.42%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 2.06%. Given that U.S. Physical Therapy, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe U.S. Physical Therapy, Inc. is more attractive than Pediatrix Medical Group, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.290, which suggesting that the stock is 28.981% more volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.542%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.06%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. U.S. Physical Therapy, Inc.'s net income of $19.7M is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 36.80x while Pediatrix Medical Group, Inc.'s PE ratio is 11.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.75x versus 0.99x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of -22162.75%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat Kindly MD, Inc.'s return on equity of -91.57%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 20.42%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 211.41%. Given that Kindly MD, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe Kindly MD, Inc. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.290, which suggesting that the stock is 28.981% more volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.06%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. U.S. Physical Therapy, Inc.'s net income of $19.7M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 36.80x while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.75x versus 11.25x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of -10.08%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 20.42%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 81.06%. Given that The Oncology Institute, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe The Oncology Institute, Inc. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.290, which suggesting that the stock is 28.981% more volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.902%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.06%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. U.S. Physical Therapy, Inc.'s net income of $19.7M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 36.80x while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.75x versus 0.67x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.